

NOW SHOWING IBS-D MULTISYMPTOM RELIEF

FOR ADULT PATIENTS WITH IBS-D¹⁻³

Short-term therapy

2 weeks of treatment for
up to 6 months of relief
of abdominal pain and
diarrhea^{1-3,*}

Median of 10 weeks
(range of 6 to 24 weeks).

Patients who experience
recurrence can be retreated
up to 2 times.

*See TARGET 1, 2, and 3
study data sections.

**#1 prescribed
medication
approved for
IBS-D^{4,†}**

IBS-D, irritable bowel syndrome with diarrhea.

[†]Based on aggregated total of all prescribers as of June 2023.⁴

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please see additional Important Safety Information throughout and [full Prescribing Information](#).

Xifaxan[®]
rifaximin 550 mg tablets

IBS-D can be diagnosed in adults based on symptoms alone⁵⁻⁷



Evaluate patient history based on Rome IV criteria for IBS-D

- Abdominal pain at least 1 day per week for the past 3 months* associated with 2 or more of the following
 - Defecation
 - Change in stool frequency
 - Change in stool form
- Use the 25% Rule:
 - <25% hard, lumpy stool,
 - >25% loose, watery stool



Exclude alarm features

- Symptom onset after age 50
- Severe or worsening symptoms
- Weight loss
- Nocturnal diarrhea
- Rectal bleeding
- Iron-deficiency anemia
- Family history of colorectal cancer, celiac disease, IBD



Use physical exam and limited diagnostic testing

In diagnosed patients

97.1% were accurately diagnosed with IBS using symptom-based criteria^{8,†}

Interpreting Rome IV for providers⁹

In 2021, the Rome Foundation proposed modified criteria for application of the Rome IV diagnostic criteria to the clinical practice setting. The intent was to allow clinicians to make a diagnosis and reduce unnecessary diagnostic testing. These criteria do not replace the standard Rome IV criteria for clinical trials or epidemiologic or pathophysiologic studies.

Nature of symptoms

The qualitative features of the Rome IV criteria must be met.

Bothersomeness

Patients should have sufficiently bothersome symptoms to seek care or affect daily activity.

Frequency

A frequency lower than the Rome IV threshold is permitted, provided that the symptoms are bothersome enough to interfere with daily activity or require treatment.

Duration

To provide some assurance that other diagnoses have been excluded, symptoms should be present for the previous 8 weeks.† The Rome IV requirement of a 3-month duration* of symptoms is not required.

IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.

*With symptom onset at least 6 months prior to diagnosis.⁵

†Population sample of 5931 adults using Rome IV Diagnostic Questionnaires.⁸

‡Exceptions are when a clinician needs to make an earlier diagnosis and is satisfied that the medical evaluation excludes other disease or for diagnoses where the symptoms occur infrequently and intermittently.⁹

More than 70% of patients diagnosed with IBS-D experienced multiple symptoms^{10,*}


2015 AGA "IBS in America" Online Survey (n=1001):
The most common symptoms reported in patients with IBS-D included




**ABDOMINAL
PAIN**



**LOOSE,
WATERY
STOOLS**



URGENCY



BLOATING

Multiple symptoms experienced during the past 12 months*


Percentage of patients with IBS-D who responded experiencing these symptoms.

*Data from the "IBS in America" online survey conducted September 14, 2015, through October 29, 2015, for the American Gastroenterological Association (AGA) by GfK Public Affairs & Corporate Communications with financial support from Ironwood Pharmaceuticals, Inc. and Allergan plc. Respondents with an IBS-D diagnosis (n=1001) and respondents with undiagnosed IBS-D (n=586) were asked the following question about a list of symptoms: "Which of the following symptoms have you experienced during the past 12 months?" Data shown reflect the responses of those with an IBS-D diagnosis. These symptoms are not inclusive of all the IBS-D symptoms reported within the survey and treatment was not assessed.

Studies show that many patients with IBS-D have a bacterial imbalance¹¹⁻¹³

In a US clinical trial, the majority of patients with IBS-D had an abnormal composition of bacteria in the gut^{14,*}

Bacterial imbalance has been linked to multiple symptoms of IBS-D^{2,11,15}



Additional studies are needed to further clarify the role of gut microbiota in IBS.

XIFAXAN is believed to affect an underlying factor of IBS-D by directly attacking bacteria in the gut that may be linked to IBS-D symptoms^{1,11,14,33-35}

- Blocks one of the steps in the transcription of bacterial DNA to RNA
- Inhibits bacterial protein synthesis
- Inhibits bacterial growth

Mechanism of action is unknown and does not imply clinical efficacy

XIFAXAN is the only FDA-approved, nonsystemic IBS-D treatment that alters the microbiome^{1,14}

- Less than 0.4% is absorbed from the GI tract
- There is an increased systemic exposure in patients with severe hepatic impairment; caution should be exercised when administering XIFAXAN to these patients

5-HT, serotonin; SCFA, short-chain fatty acids.

*Data from 93 patients with IBS-D in a prospective TARGET 3 substudy that used lactulose breath testing to predict response to XIFAXAN.¹⁴

IMPORTANT SAFETY INFORMATION (continued)

- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information throughout and full Prescribing Information.



XIFAXAN was given a strong recommendation* to treat global IBS-D symptoms in the 2020 American College of Gastroenterology (ACG) Clinical Guideline on Managing IBS^{5,†}

[†]Based on a moderate quality of evidence.[‡]

*Strength of recommendation: Strong=Most patients should receive the recommended course of action. Conditional=Many patients should have this recommended course of action, but different choices may be appropriate for some patients.

[‡]Summary of quality of evidence: High=The estimate of effect is unlikely to change with new data. Moderate=The estimate of effect is uncertain.

Questions and statements used to provide recommendations were based on response to global IBS-D symptoms.

IMPORTANT SAFETY INFORMATION (continued)


- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

**Please see additional Important Safety Information throughout
and full Prescribing Information.**

In adults with IBS-D

2 weeks of XIFAXAN provided significant relief of abdominal pain and diarrhea^{1,2,*}

Percentage of composite efficacy responders[†] in TARGET 1 and 2 during the months following 2 weeks of treatment (pooled analysis)



TARGET 1 and 2 study design

Two identical phase 3, randomized, double-blind, placebo-controlled trials were conducted over a 3-month period. A total of 1258 patients meeting Rome II criteria for IBS-D were to receive XIFAXAN 550 mg 3 times a day (n=624) or placebo (n=634) for 14 days.

Primary endpoint: Adequate relief of IBS-D signs and symptoms for at least 2 of 4 weeks during the month following 14 days of treatment, with adequate relief defined as a response of “yes” to the weekly Subject Global Assessment (SGA) question: “In regards to your IBS-D symptoms, compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS-D symptoms? [Yes/No].”

Primary endpoint results: 41% of patients (254 of 624) in the XIFAXAN 550 mg group, 31% of TARGET 1 placebo group (98 of 314), and 32% of TARGET 2 placebo group (103 of 320) experienced adequate relief of IBS-D signs and symptoms.

Secondary endpoint: In both studies, more patients in the XIFAXAN 550 mg group had adequate relief of global IBS-D symptoms (see primary endpoint for definition) within the first month compared with the placebo group. Relief continued during the first 2 months and throughout all 3 months in both studies. TARGET 1 odds ratio: 1.35 (95% CI: 1.00-1.82). TARGET 2 odds ratio: 1.52 (95% CI: 1.13-2.03).

Composite endpoint: Responder defined by a $\geq 30\%$ decrease from baseline in abdominal pain, with a weekly mean stool consistency score of < 4 (loose stool) for ≥ 2 weeks during the month following 2 weeks of treatment.

*Patients who experience recurrence can be retreated up to 2 times.¹

[†]Efficacy responder defined as a $\geq 30\%$ decrease from baseline in abdominal pain, with a weekly mean stool consistency score of < 4 (loose stool) for ≥ 2 weeks during the month following 2 weeks of treatment.¹

¹P < 0.001 , represents pooled data.


IMPORTANT SAFETY INFORMATION (continued)

- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.

Please see additional Important Safety Information throughout and full Prescribing Information.

XIFAXAN provided relief of bloating and urgency^{2,36}

Percentage of **BLOATING** responders based on weekly responses in TARGET 1 and 2²




*Represents pooled analysis.

Key secondary endpoint: The proportion of patients who achieved adequate relief of IBS-D–related bloating (ie, responders) for at least 2 of 4 weeks during the month following 14 days of treatment.²

A bloating responder was defined as a patient who responded “yes” to the weekly question: “In regards to your IBS-D symptom of bloating, compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS-D symptom of bloating? [Yes/No].”^{2,1}

¹Responses were given during the first 4 weeks of the treatment-free period following 2 weeks of active treatment (primary evaluation period).²

Percentage of **URGENCY** responders based on weekly responses in TARGET 1, 2, and 3 in a pooled post hoc analysis³⁷



Secondary endpoint: Change from baseline to each week during the 12-week study duration for sense of urgency.^{38,39}

An urgency responder was defined as a patient with a $\geq 30\%$ decrease from baseline in the percentage of days with urgency for at least 2 of 4 weeks during the month following 14 days of treatment. Urgency was determined based on patient response of “yes” to the daily question: “Have you felt or experienced a sense of urgency today? [Yes/No].”³⁷

Stool frequency (number of bowel movements per day) was assessed as a secondary endpoint, but there was no meaningful difference between XIFAXAN and placebo.^{38,39}

IMPORTANT SAFETY INFORMATION (continued)

- In clinical studies, the most common adverse reactions for XIFAXAN in IBS-D ($\geq 2\%$) were nausea (3%) and ALT increased (2%).
- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.

Please see additional Important Safety Information throughout and full Prescribing Information.

Efficacy and safety evaluation of TARGET 3: an extended retreatment trial^{1,3}

Open-label phase (N=2438)

44% XIFAXAN 1st treatment responders
(n=1074/2438)

Symptom recurrence 64%
(n=692/1074)

10 weeks
Median time to recurrence during treatment-free observation
(range of 6 to 24 weeks)

Double-blind repeat treatment
(n=636 randomized)

Primary endpoint
38% experienced significant improvement in stool consistency and abdominal pain
(n=125/328, $P < 0.05$ vs **31.5%** for placebo, n=97/308)

36% of open-label responders (n=382/1074) had no reported symptom recurrence within 6 months
36% of open-label responders did not experience relapse during the 18-week observation phase before being withdrawn from the trial for any reason

TARGET 3 study design

This trial included an open-label phase followed by a randomized, placebo-controlled phase, with the aim of determining the efficacy and safety of repeat treatment with XIFAXAN in patients with IBS-D who had responded to a 2-week course of XIFAXAN and subsequently experienced IBS-D symptom recurrence.

A responder was defined as a patient experiencing a $\geq 30\%$ improvement from baseline in the weekly average abdominal pain score (based on daily self-reports) and a $\geq 50\%$ reduction in the number of days in a week with a daily stool consistency of Bristol Stool Form Scale type 6 or 7 (mushy or watery) for ≥ 2 of the 4 weeks after treatment.

Recurrence was defined as the return of abdominal pain or lack of stool consistency for 3 weeks of a rolling 4-week period.

Primary endpoint: The proportion of patients who were responders to repeat treatment in both IBS-D-related abdominal pain and stool consistency during the 4 weeks following the first repeat treatment course.


IMPORTANT SAFETY INFORMATION (continued)

- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

Please see additional Important Safety Information throughout and full Prescribing Information.



With repeated treatment, **recurring symptoms were less severe than baseline**^{1,3,*}



Change from baseline in mean daily global IBS-D symptom score during the first and second repeat treatment double-blind phases. Global daily IBS-D symptom score is based on a 6-question patient assessment related to bowel movements, urgency, abdominal pain, bloating, and severity of symptoms. All patients in the XIFAXAN arm of this study were given second retreatment/third treatment regardless of symptom recurrence status.³

*Baseline defined as study entry into open-label phase.³

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please see additional Important Safety Information throughout and full Prescribing Information.

In adults with IBS-D

XIFAXAN has a well-established safety profile¹

Side effects at rates similar to placebo

Adverse event	TARGET 1 and 2		TARGET 3	
	XIFAXAN (n=624)	Placebo (n=634)	XIFAXAN (n=328)	Placebo (n=308)
Nausea	3%	2%	2%	1%
ALT increased*	NA	NA	2%	1%

- Constipation was observed in 0.3%-0.6% of patients treated with XIFAXAN^{3,40}
- Did not cause any clinically relevant antibiotic resistance after 1 to 3 treatment cycles⁴¹

ALT, alanine aminotransferase; NA, not available.

*Most of the events of ALT increase were due to transient increases that resolved over time and were not temporally associated with study drug treatment.³



IMPORTANT SAFETY INFORMATION (continued)

- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information throughout and full Prescribing Information.

2 weeks of XIFAXAN delivered lasting relief of multiple symptoms¹⁻³

Most treatments manage symptoms with continuous daily therapy, but XIFAXAN is different^{1,42,43}



One 550-mg tablet 3 times a day with or without food¹



2 weeks of treatment, not continuous, daily prescription medication¹



Patients who complete initial treatment can be **retreated up to 2 times** for recurrence¹



Provides relief of multiple IBS-D symptoms: abdominal pain, diarrhea, bloating, and urgency^{1,2,36,37}



XIFAXAN was given a strong recommendation[†] to treat global IBS-D symptoms in the 2020 ACG Clinical Guideline on Managing IBS^{5,‡}

[‡]Based on a moderate quality of evidence.⁵

*The ICD-10 codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

[†]Strength of recommendation: Strong=Most patients should receive the recommended course of action. Conditional=Many patients should have this recommended course of action, but different choices may be appropriate for some patients.⁵

⁵Summary of quality of evidence: High=The estimate of effect is unlikely to change with new data. Moderate=The estimate of effect is uncertain.⁵

IMPORTANT SAFETY INFORMATION (continued)

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

Please see additional Important Safety Information throughout and full Prescribing Information.

XIFAXAN has a straightforward prior authorization (PA) process

The XIFAXAN PA process is a simple way to help your adult patients diagnosed with IBS-D gain access to the treatment you prescribe

When a PA is required, be sure the following information is included and accurate:

- ✓ **Indication of IBS-D: K58.0, the ICD-10 code for IBS-D^{44,*}**
- ✓ **Age: 18 years or older¹**
- ✓ **Approved dosing for IBS-D: #42 XIFAXAN 550-mg tablets, 3 times a day by mouth for 2 weeks¹**
- ✓ **Previous therapies tried and failed** (eg, antidiarrheals, antispasmodics, loperamide, SSRIs, TCAs, and other OTC medications)

Remember to check for accurate and complete prescribing in EHR/EMR and on Rx, and consider XIFAXAN 550 mg for your system's EHR preference list or favorites. For PA support for XIFAXAN, go to covermymeds.com or call **1-866-452-5017**.

Help your patients start and stay on XIFAXAN as required



The most common reasons for treatment rejection are failure to initiate a PA, providing inaccurate information, and/or submitting incomplete forms. Watch out for these errors when filling out a PA:

- Missing signature
- Absent or invalid ICD-10 code
- Incorrect dosing for the indication

Initiate PAs in office vs awaiting pharmacy initiation when necessary

- In general, PAs proactively generated by prescribers had a higher dispense rate than PAs initiated by pharmacies⁴⁵

98% of commercially insured patients have coverage for XIFAXAN^{46,*†}

100% of Medicare Part D patients have coverage for XIFAXAN^{46,*†}

*See ICD-10 code disclaimer on page 11.

†Formulary status subject to change.

IMPORTANT SAFETY INFORMATION (continued)

- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.

Please see additional Important Safety Information throughout and full Prescribing Information.


Help your eligible* patients save on XIFAXAN



XIFAXAN Instant Savings Card program may help eligible,* commercially insured patients with coverage for XIFAXAN pay as little as \$0



Patients who need assistance with their monthly copays can call **1-866-XIFAXAN (1-866-943-2926)**



Patients can text **"PAY 0"** to activate

93%

of eligible,* commercially insured patients who had coverage for XIFAXAN

**PAID \$10
OR LESS**

for their prescription when a copay card or e-voucher was applied in the last year (June 2022 to June 2023)⁴⁷

*Patient is not eligible if he/she participates in, seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state healthcare program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full-cash-paying patients. Maximum benefits and other restrictions apply. Visit <https://xifaxan.copaysavingsprogram.com> or call 1-866-XIFAXAN for full eligibility criteria, terms, and conditions.

For more Copay Card details, [click here](#)

Please see **Important Safety Information** throughout and **full Prescribing Information**.

References: 1. XIFAXAN. Prescribing information. Salix Pharmaceuticals; 2023. Accessed November 3, 2023. <https://shared.salix.com/globalassets/pi/xifaxan550-pi.pdf> 2. Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med*. 2011;364(1):22-32. doi:10.1056/NEJMoa1004409 3. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. *Gastroenterology*. 2016;151(6):1113-1121. doi:10.1053/j.gastro.2016.08.003 4. Data on file. LAAD June 2023. Salix Pharmaceuticals, Bridgewater, NJ. 5. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. *Am J Gastroenterology*. 2021;116(1):17-44. doi:10.14309/ajg.000000000001036 6. Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. *J Clin Med*. 2017;6(11):99. doi:10.3390/jcm6110099 7. Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. *Gastroenterology*. 2022;163(1):137-151. doi:10.1053/j.gastro.2022.04.017 8. Palsson OS, Whitehead WE, van Tilburg MAL, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. *Gastroenterology*. 2016;150(6):1481-1491. doi:10.1053/j.gastro.2016.02.014 9. Drossman DA, Tack J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. *Gastroenterology*. 2022;162(3):675-679. doi:10.1053/j.gastro.2021.11.019 10. American Gastroenterological Association. IBS in America: survey summary findings. December 2015. Accessed August 1, 2023. <http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf> 11. Zhong W, Lu X, Shi H, et al. Distinct microbial populations exist in the mucosa associated microbiota of diarrhea predominant irritable bowel syndrome and ulcerative colitis. *J Clin Gastroenterol*. 2019;53(9):660-672. doi:10.1097/MCG.0000000000000961 12. Casén C, Vebø HC, Sekeja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. *Aliment Pharmacol Ther*. 2015;42(1):71-83. doi:10.1111/apt.13236 13. Kassinen A, Krogus-Kurikka L, Mäki-Vuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. *Gastroenterology*. 2007;133(1):24-33. doi:10.1053/j.gastro.2007.04.005 14. Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. *Am J Gastroenterol*. 2019;114(12):1886-1893. doi:10.14309/ajg.000000000000444 15. Sundin J, Aziz I, Nordlander S, et al. Evidence of altered mucosa-associated and fecal microbiota composition in patients with irritable bowel syndrome. *Sci Rep*. 2020;10(1):593. doi:10.1038/s41598-020-57468-y 16. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. *Gut*. 2001;48(1):14-19. doi:10.1136/gut.48.1.14 17. Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. *Gastroenterology*. 2006;131(4):1003-1010. doi:10.1053/j.gastro.2006.07.015 18. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. *J Gastroenterol Hepatol*. 2010;25(8):1366-1373. doi:10.1111/j.1440-1746.2010.06370.x 19. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. *Lancet*. 1998;352(9135):1187-1189. doi:10.1016/s0140-6736(98)02146-1 20. Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. *Am J Gastroenterol*. 2015;110(9):1339-1346. doi:10.1038/ajg.2015.220 21. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what's the link? *Am J Gastroenterol*. 2012;107(5):754-760. doi:10.1038/ajg.2012.5 22. Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. *Am J Gastroenterol*. 2001;96(5):1499-1506. doi:10.1111/j.1572-0241.2001.03804.x 23. Tack J, Broekaert D, Corsetti M, Fischler B, Janssens J. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. *Aliment Pharmacol Ther*. 2006;23(2):265-274. doi:10.1111/j.1365-2036.2006.02724.x 24. Houghton LA, Atkinson W, Lockhart C, Whorwell PJ, Keevil B. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. *Neurogastroenterol Motil*. 2007;19(9):724-731. doi:10.1111/j.1365-2982.2007.00943.x 25. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. *Gastroenterology*. 2006;130(1):34-43. doi:10.1053/j.gastro.2005.09.031 26. Gargari G, Taverniti V, Gardana C, et al. Fecal clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. *Environ Microbiol*. 2018;20(9):3201-3213. doi:10.1111/1462-2920.14271 27. Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. *J Gastroenterol*. 2014;49(11):1467-1476. doi:10.1007/s00535-013-0919-6 28. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. *Am J Gastroenterol*. 2009;104(2):392-400. doi:10.1038/ajg.2008.94 29. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. *Gut*. 2009;58(2):196-201. doi:10.1136/gut.2007.140806 30. Liebrechts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. *Gastroenterology*. 2007;132(3):913-920. doi:10.1053/j.gastro.2007.01.046 31. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. *Pain*. 2009;146(1-2):41-46. doi:10.1016/j.pain.2009.06.017 32. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. *Gut*. 2007;56(2):203-209. doi:10.1136/gut.2006.100594 33. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. *J Chemother*. 2008;20(2):186-194. doi:10.1179/joc.2008.20.2.186 34. Zeber-Lubecka N, Kulecka M, Ambroziewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. *Gut Microbes*. 2016;7(5):397-413. doi:10.1080/19490976.2016.1215805 35. Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. *Clin Exp Gastroenterol*. 2015;8:309-323. doi:10.2147/CEG.S89999 36. Pimentel M, Cash BD, Lacy BE, Heimanson Z, Lembo A. Assessing the efficacy of rifaximin in diarrhea-predominant irritable bowel syndrome: a post hoc analysis of two phase 3, randomized, placebo-controlled trials. Poster presented at: World Congress of Gastroenterology; October 13-18, 2017; Orlando, FL. 37. Schoenfeld PS, Brenner DM, Pichetshote N, Heimanson Z, Lacy BE. Rifaximin significantly improves bowel movement urgency in patients with irritable bowel syndrome with diarrhea: a pooled analysis of three phase 3 trials. Poster presented at: Digestive Disease Week; May 21-23, 2021; virtual. 38. Data on file. Target 1 CSR May 2010. Salix Pharmaceuticals, Bridgewater, NJ. 39. Data on file. Target 2 CSR May 2010. Salix Pharmaceuticals, Bridgewater, NJ. 40. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. *Aliment Pharmacol Ther*. 2014;39(10):1161-1168. doi:10.1111/apt.12735 41. Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. *Dig Dis Sci*. 2017;62(9):2455-2463. doi:10.1007/s10620-017-4598-7 42. Viberzi. Prescribing information. Allogram; 2020. Accessed August 4, 2023. https://www.rxabbvie.com/pdf/viberzi_pi.pdf 43. Amitriptyline HCL. Prescribing information. Sandoz; 2020. Accessed August 4, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/085966s095,085969s084,085968s096,085971s075,085967s076,085970s072bl.pdf 44. ICD-10. Centers for Medicare & Medicaid Services. Updated December 1, 2021. Accessed August 4, 2023. www.cms.gov/Medicare/Coding/ICD10 45. Data on file. XIFAXAN CMM Executive Summary 2022. Salix Pharmaceuticals, Bridgewater, NJ. 46. Data on file. MMIT September 2023. Salix Pharmaceuticals, Bridgewater, NJ. 47. Data on file. Patient Copy June 2022 to 2023. Salix Pharmaceuticals, Bridgewater, NJ.

Please see Important Safety Information throughout and full Prescribing Information.

NOW SHOWING IBS-D MULTISYMPTOM RELIEF

FOR ADULT PATIENTS WITH IBS-D¹⁻³



#1 prescribed medication approved for IBS-D^{4,*}

2 WEEKS OF XIFAXAN TREATMENT provided **LASTING RELIEF**
of abdominal pain and diarrhea^{1-3,1,†,§}

To see our commercial on the website, [click here](#)

*Based on aggregated total of all prescribers as of June 2023.⁴

†In TARGET 1 and TARGET 2, adequate relief of global IBS-D symptoms over 10 weeks post treatment. In TARGET 3, no recurrence of diarrhea/abdominal pain was observed in a proportion of open-label responders. Median time to recurrence was 10 weeks, range of 6 to 24 weeks.¹⁻³

‡Patients who experience recurrence can be retreated up to 2 times.¹

§See TARGET 1, 2, and 3 study data sections.



Excellent insurance coverage to ensure patient access

- 98% of commercially insured patients have coverage for XIFAXAN^{46,¶,#}
- 100% of Medicare Part D patients have coverage for XIFAXAN^{46,¶,#}
- 93% of eligible,^{||} commercially insured patients who had coverage for XIFAXAN paid \$10 or less for their prescription when a copay card or e-voucher was applied in the last year (June 2022 to June 2023)⁴⁷

¶Formulary status subject to change.

#See ICD-10 code disclaimer on page 11.

||See eligibility criteria on page 13.

IMPORTANT SAFETY INFORMATION


- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please see additional Important Safety Information throughout
and full Prescribing Information.



REDUCE THE REPEAT

Disrupt the pattern of overt hepatic encephalopathy (OHE) episodes with XIFAXAN¹



XIFAXAN earned the highest possible recommendation (GRADE I,A,1) by the AASLD/EASL as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a patient has a recurrence while on lactulose alone.^{2,*}

INDICATION

XIFAXAN[®] (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Please see additional Important Safety Information throughout and full Prescribing Information.

AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver.

*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is "high quality," and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is "strong," with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.²

Xifaxan[®]
rifaximin 550 mg tablets

CHRONIC LIVER DISEASE (CLD) AND CIRRHOSIS ARE A GROWING PROBLEM³

Diabetes/cerebrovascular disease (stroke)

CLD and cirrhosis had **greater mortality in patients aged 25 to 54** than diabetes or cerebrovascular disease (2019)⁴



CLD and cirrhosis were the **9th leading cause of death** in the US in 2021⁵



45% increase in total number of CLD-related hospitalizations from 2005 to 2017^{6,*}

*Rates per 1000 persons.

Patients with CLD/decompensated cirrhosis who have portal hypertension have a higher risk of complications, such as^{7,8}:



Varices



Ascites



HE

HE is a primary complication of cirrhosis²

UP TO 80%

of patients with cirrhosis will eventually develop some form of HE²

HE classification using the West Haven criteria (including minimal HE)²


Covert HE		Overt HE		
MINIMAL	GRADE 1	GRADE 2	GRADE 3	GRADE 4
<ul style="list-style-type: none"> No outward signs; deficits in psychometric or neuropsychological tests 	<ul style="list-style-type: none"> Lack of awareness Euphoria or anxiety Short attention span Inability to add or subtract Altered sleep 	<ul style="list-style-type: none"> Lethargy/apathy No sense of time Personality change Inappropriate behavior Dyspraxia Asterixis 	<ul style="list-style-type: none"> Somnolence to semistupor Responsiveness to stimuli Confusion Disorientation Bizarre behavior 	<ul style="list-style-type: none"> Coma

30% to 40% of patients with cirrhosis will develop OHE²

XIFAXAN WAS GIVEN THE HIGHEST POSSIBLE RECOMMENDATION BY THE AASLD/EASL²

Align with the guidelines by using the only FDA-approved agent indicated for the reduction in risk of OHE recurrence in adults¹

XIFAXAN earned the highest possible recommendation (GRADE I,A,1) by the AASLD/EASL as an add-on therapy to lactulose to reduce the risk of OHE recurrence after a patient has a recurrence while on lactulose alone.²



I,A,1 is the highest possible recommendation²

- GRADE I:** Proven in randomized, controlled trials
- GRADE A:** Evidence is "high quality," and further research is very unlikely to change our confidence in the estimated effect
- GRADE 1:** Recommendation is "strong," with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs

AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver.

IMPORTANT SAFETY INFORMATION (continued)

- *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued.

Please see additional Important Safety Information throughout and full Prescribing Information.


XIFAXAN CUT THE RISK OF OHE RECURRENCE AND HE-RELATED HOSPITALIZATIONS IN HALF¹

Xifaxan[®]
rifaximin 550 mg tablets

In a clinical trial of adults with OHE




Primary Endpoint

OHE recurrences during 6 months of treatment*



Secondary Endpoint

HE-related hospitalizations during 6 months of treatment



91% of patients in the placebo and XIFAXAN groups were on lactulose¹

Study design^{1,9}

- In a randomized, placebo-controlled, double-blind, multicenter, multinational, 6-month study, the efficacy of XIFAXAN 550 mg (taken orally twice a day) was evaluated in 299 adult patients
- Inclusion criteria:** Currently in remission (Conn score of 0 or 1) from HE and ≥ 2 episodes of HE associated with chronic liver disease in the previous 6 months
- Primary endpoint:** Time to first breakthrough OHE episode, defined as a marked deterioration in neurological function and an increase in Conn score to grade ≥ 2 or an increase in Conn score and asterix grade of 1 each if patient entered study at grade 0
- Key secondary endpoint:** HE-related hospitalization

XIFAXAN number needed to treat (NNT)⁹

Condition	Therapy	To Prevent One	NNT
OHE	XIFAXAN 550 mg + background lactulose ¹	OHE episode in 6 months	4
		HE-related hospitalization in 6 months	9

*Comparison of Kaplan-Meier estimates of event-free curves showed XIFAXAN significantly reduced the risk of HE breakthrough by 58% during the 6-month treatment period.¹

¹91% of patients in the XIFAXAN group were on concomitant lactulose.¹

IMPORTANT SAFETY INFORMATION (continued)

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.

Please see additional Important Safety Information throughout and full Prescribing Information.

A DEMONSTRATED SAFETY PROFILE¹

Trial 1 safety data (occurring in ≥10% of patients)

Common Adverse Reactions	XIFAXAN (N=140), n (%)	Placebo (N=159), n (%)
Peripheral edema	21 (15%)	13 (8%)
Nausea	20 (14%)	21 (13%)
Dizziness	18 (13%)	13 (8%)
Fatigue	17 (12%)	18 (11%)
Ascites	16 (11%)	15 (9%)

Adverse reactions that occurred in ≥5% but <10% of patients receiving XIFAXAN and greater than in patients who received placebo: muscle spasms, pruritus, abdominal pain, anemia, depression, nasopharyngitis, abdominal pain upper, arthralgia, dyspnea, pyrexia, and rash.

Trial 2 safety data (occurring in ≥10% of patients)*

Common Adverse Reactions	XIFAXAN + lactulose (N=108), n (%)	XIFAXAN (N=113), n (%)
Peripheral edema	15 (14%)	19 (17%)
Insomnia	15 (14%)	13 (12%)
Ascites	14 (13%)	8 (7%)
Diarrhea	13 (12%)	6 (5%)
Nausea	11 (10%)	17 (15%)
Muscle spasms	11 (10%)	9 (8%)
Constipation	9 (8%)	18 (16%)
Fatigue	9 (8%)	16 (14%)
Urinary tract infection	9 (8%)	13 (12%)
Pruritus	6 (6%)	11 (10%)
Anemia	3 (3%)	11 (10%)

Adverse reactions that occurred in ≥5% but <10% of patients receiving XIFAXAN in either treatment group: dyspnea, anxiety, abdominal pain, decreased appetite, headache, cough, renal failure acute, vomiting.

*Trial 2 safety data described in Table 2 reflect randomized patient exposure to XIFAXAN + lactulose or XIFAXAN monotherapy in an open-label, active-controlled, multicenter, 6-month trial in adults with hepatic encephalopathy.

IMPORTANT SAFETY INFORMATION (continued)

- Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.

Please see additional Important Safety Information throughout and full Prescribing Information.

ACCURACY MATTERS: CORRECTLY PRESCRIBE XIFAXAN FOR THE REDUCTION IN RISK OF OHE RECURRENCE IN ADULTS¹



One 550-mg tablet, twice daily—no dose adjustments or titrations needed¹

- There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients



Can be taken **with or without food**¹



Can be continued for as long as patient is at risk of recurrent OHE¹



When prescribing XIFAXAN, use the ICD-10 code for OHE: **K76.82** (Hepatic encephalopathy; indicate lactulose history if applicable)^{10,*}



*The ICD-10 code and all other patient-access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment, and applicable ICD-10 code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

IMPORTANT SAFETY INFORMATION (continued)

- In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
 - o HE (≥10%); Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%)
- INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
- XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

References: **1.** XIFAXAN. Prescribing information. Salix Pharmaceuticals; 2023. Accessed November 3, 2023. <https://shared.salix.com/globalassets/pi/xifaxan550-pi.pdf> **2.** Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*. 2014;60(2):715-735. doi:10.1002/hep.27210 **3.** Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. *JAMA Netw Open*. 2020;3(4):e201997. doi:10.1001/jamanetworkopen.2020.1997 **4.** Xu J, Murphy SL, Kochanek KD, Arias E. Deaths: final data for 2019. *Natl Vital Stat Rep*. 2021;70(8):1-87. doi:10.15620/cdc:106058 **5.** Chronic liver disease and cirrhosis. Centers for Disease Control and Prevention. Updated January 17, 2023. Accessed August 14, 2023. <https://www.cdc.gov/nchs/fastats/liver-disease.htm> **6.** Desai AP, Greene M, Nephew LD, et al. Contemporary trends in hospitalizations for comorbid chronic liver disease and substance use disorders. *Clin Transl Gastroenterol*. 2021;12(6):e00372. doi:10.14309/ctg.0000000000000372 **7.** Mansour D, McPherson S. Management of decompensated cirrhosis. *Clin Med (Lond)*. 2018;18(suppl 2):s60-s65. doi:10.7861/clinmedicine.18-2-s60 **8.** Garcia-Tsao G, Abralides JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. *Hepatology*. 2017;65(1):310-335. doi:10.1002/hep.28906 **9.** Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med*. 2010;362(12):1071-1081. doi:10.1056/NEJMoa0907893 **10.** ICD-10. Centers for Medicare & Medicaid Services. Updated December 1, 2021. Accessed August 4, 2023. www.cms.gov/Medicare/ICD10

Please see additional Important Safety Information throughout and full Prescribing Information.

NOW SHOWING

IBS-D MULTISYMPTOM RELIEF

FOR ADULT PATIENTS WITH IBS-D¹⁻³



#1 prescribed medication approved for IBS-D^{4,*}

2 WEEKS OF XIFAXAN TREATMENT provided **LASTING RELIEF** of abdominal pain and diarrhea^{1-3,1,4,5}

To see our commercial on the website, [click here](#)

*Based on aggregated total of all prescribers as of June 2023.⁴

¹In TARGET 1 and TARGET 2, adequate relief of global IBS-D symptoms over 10 weeks post treatment. In TARGET 3, no recurrence of diarrhea/abdominal pain was observed in a proportion of open-label responders. Median time to recurrence was 10 weeks, range of 6 to 24 weeks.³⁻³

²Patients who experience recurrence can be retreated up to 2 times.¹

³See TARGET 1, 2, and 3 study data sections.



Excellent insurance coverage to ensure patient access

- 98% of commercially insured patients have coverage for XIFAXAN^{46,47,#}
- 100% of Medicare Part D patients have coverage for XIFAXAN^{46,47,#}
- 93% of eligible,⁴⁸ commercially insured patients who had coverage for XIFAXAN paid \$10 or less for their prescription when a copay card or e-voucher was applied in the last year (June 2022 to June 2023)⁴⁷

*Formulary status subject to change.

⁴⁶See ICD-10 code disclaimer on page 11.

⁴⁸See eligibility criteria on page 13.

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

Xifaxan
rifaximin 550 mg tablets

IMPORTANT SAFETY INFORMATION

- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and [full Prescribing Information](#).



Salix Pharmaceuticals
400 Somerset Corporate Blvd., Bridgewater, NJ 08807

The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A. to Salix Pharmaceuticals or its affiliates. © 2024 Salix Pharmaceuticals or its affiliates. XIFI.0054.USA.23V2.0